Inspire Veterinary Partners Reports First Quarter 2024 Financial Results
Inspire Veterinary Partners (NASDAQ: IVP) reported a 13% increase in total revenue for Q1 2024, reaching $4.8 million, driven by a 15% rise in service revenue and a 6% increase in product revenue. The company highlighted a positive same-store revenue growth of 3% and implemented cost-reduction initiatives to enhance cash flow. Despite these gains, the net loss widened to $3.4 million from $1.5 million in the prior year, mainly due to increased operating expenses and costs associated with public offerings and consulting services. General and administrative expenses surged to $2.9 million, including $900k in non-cash expenses. The company's cash and cash equivalents stood at $69,000 as of March 31, 2024.
- Total revenue increased by 13% to $4.8M in Q1 2024.
- Service revenue rose by 15%, reaching $3.5M.
- Product revenue increased by 6%, totaling $1.3M.
- Positive same-store revenue growth of 3% year over year.
- Implemented cost-reduction initiatives to improve cash management.
- Net loss increased to $3.4M from $1.5M in the prior year.
- General and administrative expenses rose to $2.9M, including $900k in non-cash expenses.
- Operating costs associated with animal hospitals and clinics increased.
- Costs of public offering completed in Q1 2024 contributed to the loss.
- Cash and cash equivalents were only $69,000 as of March 31, 2024.
Insights
Total revenue of
While cost reduction initiatives are promising, the cash and cash equivalents of just
Retail investors should note the balance between revenue growth and escalating expenses and watch future earnings reports for signs of profitability improvement.
The pet care industry shows strong demand and Inspire’s 15% service revenue increase underscores this trend. The acquisition of a new animal hospital also fuels growth, but integration costs are notable. The company’s focus on operating efficiencies and productivity per labor hour is key to managing costs.
Investors should keep an eye on how well Inspire integrates new acquisitions and manages expenses. The 3% same-store sales growth indicates steady demand, but balancing this with cost control will determine future success in this competitive market.
The rise in non-cash expenses, such as stock/warrants for services, suggests innovative strategies to manage cash flow but requires careful monitoring to ensure it doesn’t dilute shareholder value.
- Total revenue of
$4.8 million , a13% increase compared to the prior year quarter - Same store sales growth,
3% year over year - Cost reduction initiatives implemented to improve cash management and accelerate path to free cash flow
VIRGINIA BEACH, VA / ACCESSWIRE / May 15, 2024 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) ("Inspire" or the "Company"), an owner and provider of pet health care services throughout the U.S., today reported its financial results for the first quarter ended March 31, 2024.
First Quarter 2024 Overview
- Total revenue of
$4.8 million , an increase of13% - Services revenue of
$3.5 million , an increase of15% - Product revenue of
$1.3 million , an increase of6%
"2024 is off to a good start as we drove solid 13 percent top-line growth and believe our results highlight the broad-based growth and strong pet parent demand for our service and product offerings," said Kimball Carr, Chairman, President & Chief Executive Officer of Inspire. "In addition to record quarterly revenue, we achieved a positive same store revenue comp of
Carr added, "We are excited to see the business continue to evolve, and we remain focused on integrating and executing our newly acquired animal hospitals to provide more value to our customers. As we move through 2024,we remain confident in the sustainable, underlying demand for animal health, based on the strength of the human-animal bond and people's willingness to spend on pet health. Furthermore, we are excited about the strategic opportunities ahead and our role in continuing to drive innovation across the pet health category. The pet care industry continues to grow, and we believe we have opportunities to take advantage of that growth and drive higher returns to our shareholders."
First Quarter 2024 Operating Results
Total revenue was
General and administrative expenses were
Net loss was
Balance Sheet
As of March 31, 2024, the Company had cash and cash equivalents of approximately
About Inspire Veterinary Partners, Inc.
Inspire Veterinary Partners is an owner/operator of veterinary hospitals in the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care.
For more information, please visit: www.inspirevet.com.
Connect with Inspire Veterinary Partners, Inc.
https://www.facebook.com/InspireVeterinaryPartners/
https://www.linkedin.com/company/inspire-veterinary-partners/
Forward-Looking Statements
This press release contains forward-looking statements regarding the Company's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions related to anticipated acquisitions, or factors that result in changes to the Company's anticipated results of operations related to acquisitions. These and other risks and uncertainties are described more fully in the section captioned "Risk Factors" in the Company's public filings made with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Investor Contact
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com
General Inquires
Morgan Wood
Mwood@inspirevet.com
Inspire Veterinary Partners, Inc.
Unaudited Condensed Consolidated Balance Sheets
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 69,077 | $ | 178,961 | ||||
Accounts receivable, net | 341,488 | 28,573 | ||||||
Due from former owners | - | 32,519 | ||||||
Inventory | 545,660 | 571,512 | ||||||
Refundable income tax | 151,796 | 151,796 | ||||||
Prepaid expenses and other current assets | 2,031,311 | 388,759 | ||||||
Total current assets | 3,139,332 | 1,352,120 | ||||||
Restricted cash - non-current | 200,000 | 200,000 | ||||||
Property and equipment, net | 7,966,721 | 7,949,144 | ||||||
Right-of-use assets | 1,562,367 | 1,616,198 | ||||||
Other intangibles, net | 2,305,014 | 2,513,028 | ||||||
Goodwill | 8,147,590 | 8,147,590 | ||||||
Other assets | 73,989 | 12,895 | ||||||
Total assets | $ | 23,395,013 | $ | 21,790,975 | ||||
Liabilities and Stockholder's Deficit | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,521,759 | $ | 3,206,594 | ||||
Accrued expenses | 455,227 | 858,334 | ||||||
Cumulative Series A preferred stock dividends payable | 2,250 | 92,322 | ||||||
Operating lease liabilities | 133,113 | 141,691 | ||||||
Loan payable, net of discount | 2,338,067 | 1,713,831 | ||||||
Bridge note, net of discount | - | - | ||||||
Convertible note payable | 500,000 | - | ||||||
Convertible debentures, net of issuance costs | - | 100,000 | ||||||
Notes payable, net of discount | 1,501,562 | 1,469,043 | ||||||
Total current liabilities | 8,451,978 | 7,581,815 | ||||||
Operating lease liabilities, non-current | 1,482,514 | 1,514,044 | ||||||
Notes payable - noncurrent | 13,190,668 | 13,483,375 | ||||||
Total liabilities | 23,125,160 | 22,579,234 | ||||||
COMMITMENTS AND CONTINGENCIES (Note 12) | ||||||||
STOCKHOLDER'S EQUITY (DEFICIT) | ||||||||
Common stock - Class A, | 74 | 7 | ||||||
Common stock - Class B, | 389 | 389 | ||||||
Convertible series A preferred stock, | 8 | 40 | ||||||
Additional paid in capital | 25,118,701 | 20,426,562 | ||||||
Accumulated deficit | (24,849,319 | ) | (21,215,257 | ) | ||||
Total stockholder's equity (deficit) | 269,853 | (788,259 | ) | |||||
Total liabilities and stockholder's equity (deficit) | $ | 23,395,013 | $ | 21,790,975 |
Inspire Veterinary Partners, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Operations
| For the Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
Service revenue | $ | 3,545,599 | $ | 3,072,885 | ||||
Product revenue | 1,285,968 | 1,209,630 | ||||||
Total revenue | 4,831,567 | 4,282,515 | ||||||
Operating expenses | ||||||||
Cost of service revenue (exclusive of depreciation and amortization, shown separately below) | 2,709,147 | 2,307,903 | ||||||
Cost of product revenue (exclusive of depreciation and amortization, shown separately below) | 1,016,107 | 879,400 | ||||||
General and administrative expenses | 2,873,343 | 1,801,659 | ||||||
Debt extinguishment loss | 728,278 | - | ||||||
Depreciation and amortization | 367,197 | 298,492 | ||||||
Total operating expenses | 7,694,072 | 5,287,454 | ||||||
Loss from operations | (2,862,505 | ) | (1,004,939 | ) | ||||
Other income (expenses): | ||||||||
Interest income | 2 | 1 | ||||||
Interest expense | (559,289 | ) | (545,435 | ) | ||||
Other income | - | 11,424 | ||||||
Total other expenses | (559,287 | ) | (534,010 | ) | ||||
Loss before income taxes | (3,421,792 | ) | (1,538,949 | ) | ||||
Benefit for income taxes | - | - | ||||||
Net loss | (3,421,792 | ) | (1,538,949 | ) | ||||
Dividend on convertible series A preferred stock | (214,520 | ) | - | |||||
Net loss attributable to class A and B common stockholders | $ | (3,636,312 | ) | $ | (1,538,949 | ) | ||
Net loss per Class A and B common shares: | ||||||||
Basic and diluted | $ | (8.97 | ) | $ | (29.20 | ) | ||
Weighted average shares outstanding per Class A and B common shares: | ||||||||
Basic and diluted | 405,484 | 52,705 | ||||||
Inspire Veterinary Partners, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Cash Flows
| For the Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (3,421,792 | ) | $ | (1,538,949 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 347,382 | 298,492 | ||||||
Amortization of debt issuance costs | 15,825 | 70,212 | ||||||
Amortization of debt discount | 379,313 | 242,631 | ||||||
Amortization of operating right of use assets | 53,831 | 59,036 | ||||||
Issuance of warrants to CEO | - | 2,701 | ||||||
Issuance of class A common stock for services | 286,696 | - | ||||||
Loss on debt modification | 728,278 | - | ||||||
Issuance of class A common stock in connection with general release agreement | 20,000 | - | ||||||
Issuance of Class A common stock and pre-funded warrants in connection with commitment shares | 600,000 | - | ||||||
Changes in operating assets and liabilities, net of effect of acquisitions: | ||||||||
Accounts receivable | (312,915 | ) | (70,553 | ) | ||||
Due from former owners | 32,519 | 37,425 | ||||||
Inventory | 25,852 | (18,459 | ) | |||||
Prepaid expenses and other current assets | (1,642,552 | ) | 60,414 | |||||
Other assets | (61,094 | ) | (70,431 | ) | ||||
Accounts payable | 315,165 | 550,043 | ||||||
Accrued expenses | (403,107 | ) | 118,450 | |||||
Cumulative Series A preferred stock dividends payable | (92,322 | ) | - | |||||
Operating lease liabilities | (40,108 | ) | (50,467 | ) | ||||
Net cash used in operating activities | (3,169,029 | ) | (309,455 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchase of property and equipment | (156,945 | ) | (14,002 | ) | ||||
Net cash used in investing activities | (156,945 | ) | (14,002 | ) | ||||
Cash flows from financing activities: | ||||||||
Proceeds from issuance of class A common stock and pre-funded warrants, net of issuance costs | 3,375,458 | - | ||||||
Net proceeds from loan payable | 549,185 | - | ||||||
Payments on loan payable | (1,032,540 | ) | - | |||||
Proceeds from issuance of convertible series A preferred stock | 200,000 | - | ||||||
Proceeds from convertible note payable | 500,000 | - | ||||||
Repayment of note payable | (276,013 | ) | (176,931 | ) | ||||
Proceeds from issuance of convertible debentures | - | 650,000 | ||||||
Repayment of convertible debentures | (100,000 | ) | - | |||||
Net cash provided by financing activities | 3,216,090 | 473,069 | ||||||
Net increase (decrease) in cash, cash equivalents and restricted cash | (109,884 | ) | 149,612 | |||||
Cash, cash equivalents and restricted cash, beginning of period | 378,961 | 444,253 | ||||||
Cash, cash equivalents and restricted cash, end of period | $ | 269,077 | $ | 593,865 | ||||
Supplemental Disclosure of Cash Flow Information | ||||||||
Interest payments during the year | $ | 1,316,378 | $ | 239,430 | ||||
Income taxes paid (refunded) | $ | - | $ | (188,952 | ) | |||
Noncash investing and financing activity | ||||||||
Series A Preferred Stock Dividend Paid-in-Kind | $ | 212,270 | $ | - | ||||
SOURCE: Inspire Veterinary Partners, Inc.
View the original press release on accesswire.com
FAQ
What was Inspire Veterinary Partners' total revenue for Q1 2024?
How much did Inspire Veterinary Partners' service revenue increase in Q1 2024?
What was the percentage growth in product revenue for Inspire Veterinary Partners in Q1 2024?
What was Inspire Veterinary Partners' net loss in Q1 2024?
How much did Inspire Veterinary Partners' general and administrative expenses total in Q1 2024?
What were Inspire Veterinary Partners' cash and cash equivalents as of March 31, 2024?
What cost-reduction measures did Inspire Veterinary Partners implement in Q1 2024?
What was the same-store revenue growth for Inspire Veterinary Partners in Q1 2024?
What factors contributed to Inspire Veterinary Partners' increased net loss in Q1 2024?
